[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354974-105":59,"doc-detail-354974-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","temporal-dynamics-of-mesenchymal-stem-cell-administration-influence-immune-modulation-in-a-4t1-breast-cancer-model","Temporal dynamics of mesenchymal stem cell administration influence immune modulation in a 4T1 breast cancer model","","Mesenchymal stem cells (MSCs) are recognized for their capacity to modulate immune responses, including those directed against tumors. In this study, we investigated the temporal effects of MSCs administration on anti-tumor immunity in a murine 4T1 breast cancer model. BALB/c mice were intraperitoneally injected with MSCs either 24 h or 14 days after orthotopic implantation of 4T1 mammary carcinoma cells. Early MSC administration enhanced antitumor immune phenotypes, reduced tumor growth, and prolonged survival, while late administration promoted immunosuppression, immune evasion, and tumor progression.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/temporal-dynamics-of-mesenchymal-stem-cell-administration-influence-immune-modulation-in-a-4t1-breast-cancer-model/354974/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/temporal-dynamics-of-mesenchymal-stem-cell-administration-influence-immune-modulation-in-a-4t1-breast-cancer-model/354974.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does the timing of MSC administration affect tumor outcome in the 4T1 breast cancer model?","Question",{"text":113,"@type":114},"Early MSC administration (24 h) enhanced antitumor immune phenotypes and correlated with reduced tumor growth and prolonged survival. Late administration (14 days) promoted immunosuppression, immune evasion, and increased tumor progression.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What immune changes are associated with early MSC administration (MSC1d)?",{"text":118,"@type":114},"MSC1d increased activity and presence of NK cells, dendritic cells, macrophages, and T lymphocytes, along with higher pro-inflammatory and anti-tumor cytokines (e.g., TNF-α, IFN-γ, IL-6, IL-17) and reduced immunosuppressive cytokines (TGF-β, IL-10).",{"name":120,"@type":111,"acceptedAnswer":121},"What immunosuppressive features characterize late MSC administration (MSC14d)?",{"text":122,"@type":114},"MSC14d was linked to decreased IFN-γ+ and IL-17+ NK1.1+ cells, reduced cytotoxic immune subsets, and expanded Treg-like populations. Serum TGF-β and VEGF levels were also significantly elevated in the MSC14d group.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354974,1790164446,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Temporal dynamics of mesenchymal stem cell administration influence immune modulation in a 4T1 breast cancer model  \nDragana Papic 1, Dragica Pavlovic 1, Danijela Niciforovic2, Vladimir Jurisic3, and Vladislav Volarevic 1,4  \nCell Transplantation Volume 35: 1–19  \n© The Author(s) 2026  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/09636897251414744](DOI: 10.1177/09636897251414744)[ ](DOI: 10.1177/09636897251414744)[journals.sagepub.com/home/cll](journals.sagepub.com/home/cll)  \nAbstract  \nMesenchymal stem cells (MSCs) are recognized for their capacity to modulate immune responses, including those directed against tumors. In this study, we investigated the temporal effects of MSCs administration on anti-tumor immunity in amurine 4T1 breast cancer model. BALB/c mice were intraperitoneally injected with MSCs either 24 h (MSC1d) or 14 days (MSC14d) after orthotopic implantation of 4T1 mammary carcinoma cells. Early MSC administration (MSC1d) exhibited changes in immune cell phenotypes consistent with enhanced antitumor potential, including increased activity of natural killer (NK) cells, dendritic cells (DCs), macrophages, and T lymphocytes. These immunological changes correlated with reduced tumor growth and prolonged survival. Mice in the MSC1d group exhibited elevated serum levels of pro-inflammatory and anti-tumor cytokines (TNF-α, IFN-γ, IL-6, and IL-17), alongside decreased concentrations of immunosuppressive cytokines (TGF-β and IL-10). Tumor tissue analysis revealed increased infiltration of NK cells expressing markers associated with antitumor activity (IFN-γ-producing CD178⁺), CD80⁺/CD86⁺/I-A⁺ TNF-α-producing DCs, Th1-type CD4⁺ T cells, and Granzyme B-expressing CD8⁺ cytotoxic T lymphocytes (CTLs). Additionally, spleens of MSC1d-treated mice displayed significantly elevated populations of CD11c⁺ DCs, TNF-α/IFN-γ-secreting NK cells, CD4⁺ Th1 and Th17 cells, and CD8⁺ CTLs expressing markers associated with cytotoxic function (TNF-α, IFN-γ, and IL-17). Conversely, late MSCs administration (MSC14d) was associated with immunosuppression. Tumors from MSC14d-treated mice showed a decreased presence of IFN-γ⁺ and IL-17⁺ NK1.1 ⁺ cells, F4/80⁺ macrophages, IL-12⁺ DCs, and cytotoxic T cells. Spleens from these mice revealed a significant expansion of regulatory T cell (Treg)-like populations, including CD25⁻ , FoxP3⁻ , CD25⁺ FoxP3⁻ cells, and TGF-β/ IL-10-producing CD3⁺ and CD4⁺ T cells. Furthermore, serum levels of immunosuppressive mediators TGF-β and vascular endothelial growth factor (VEGF) were significantly elevated in the MSC14d group. Collectively, these findings demonstrate that the immunomodulatory effects of MSCs on breast cancer are highly dependent on the timing of their administration. Mesenchymal stem cells delivered during early tumor development enhance phenotypes consistent with antitumor potential and suppress tumor progression, whereas administration during later stages promotes immune evasion and tumor growth.  \nKeywords  \nMSCs, 4T1, breast cancer, immune response, regenerative medicine  \nReceived: August 27, 2025; revised: December 12, 2025; accepted: December 23, 2025  \n1 Department of Genetics, Center for Harm Reduction of Biological and Chemical Hazards, Faculty of Medical Sciences, University of Kragujevac,  \nKragujevac, Serbia  \n2Center for Internal Oncology, University Clinical Center Kragujevac, Kragujevac, Serbia 3Patophysiology Department, Faculty of Medical Science, University of Kragujevac, Kragujevac, Serbia  \n4Department of Microbiology and Immunology Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia  \nCorresponding Authors:  \nDragana Papic, Department of Genetics, Center for Harm Reduction of Biological and Chemical Hazards, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, Kragujevac 34000, Serbia.  \nEmail: [drmiloradovic7@gmail.com](drmilo","cbCaigXil6vRsYAS","https://ap.wps.com/l/cbCaigXil6vRsYAS","pdf",5643121,"English","# Abstract\n## Introduction\n## Graphical abstract","[{\"question\":\"How does the timing of MSC administration affect tumor outcome in the 4T1 breast cancer model?\",\"answer\":\"Early MSC administration (24 h) enhanced antitumor immune phenotypes and correlated with reduced tumor growth and prolonged survival. Late administration (14 days) promoted immunosuppression, immune evasion, and increased tumor progression.\"},{\"question\":\"What immune changes are associated with early MSC administration (MSC1d)?\",\"answer\":\"MSC1d increased activity and presence of NK cells, dendritic cells, macrophages, and T lymphocytes, along with higher pro-inflammatory and anti-tumor cytokines (e.g., TNF-α, IFN-γ, IL-6, IL-17) and reduced immunosuppressive cytokines (TGF-β, IL-10).\"},{\"question\":\"What immunosuppressive features characterize late MSC administration (MSC14d)?\",\"answer\":\"MSC14d was linked to decreased IFN-γ+ and IL-17+ NK1.1+ cells, reduced cytotoxic immune subsets, and expanded Treg-like populations. Serum TGF-β and VEGF levels were also significantly elevated in the MSC14d group.\"}]","Temporal dynamics of mesenchymal stem cell administration influence immune modulation in a 4T1 breast cancer model | PDF",1790115198,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97b12218b9ec99ea2a5898568e8a21ea.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a9399d940ae6dc8b474a1b8e41c6e9e.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51f21c5ecb9a03828442e5bfa449089f.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b01a8c8c25c5e8e5b2d48e85eb6ccaf4.webp",980,1268]